Trial Profile
A prospective,open,single-center study of apatinib in patients with recurrent or metastatic cervical carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 04 Jul 2018 New trial record